When the FDA granted Biogen an accelerated approval for Biogen’s Aduhelm, it wasn’t just Alzheimer’s patients who got their hopes up.
There is, for instance, a related condition called cerebral amyloid angiopathy (CAA) — which, like Alzheimer’s, is thought to be triggered by accumulation of beta amyloid deposits. The difference is that the amyloid is deposited in vessels in the brain rather than as plaques, potentially leading to bleeding and injury. And patients wanted to know: Since Aduhelm was approved on its ability to clear the very same protein that’s causing their disease, should they be taking it off-label?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 111,100+ biopharma pros reading Endpoints daily — and it's free.
"really" - Google News
July 06, 2021 at 05:07PM
https://ift.tt/3xrEWao
Scoop: Bob Nelsen is building a Really Big Neuroscience Company - Endpoints News
"really" - Google News
https://ift.tt/3b3YJ3H
https://ift.tt/35qAk7d
Bagikan Berita Ini
0 Response to "Scoop: Bob Nelsen is building a Really Big Neuroscience Company - Endpoints News"
Post a Comment